Champions Oncology (CSBR) Cash & Equivalents (2010 - 2026)

Champions Oncology's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 121.74% year-over-year to $7.1 million; the TTM figure through Jan 2026 stood at $7.1 million (up 121.74% YoY), while the FY2025 annual figure was $9.8 million, up 273.76% from the prior year.
• Cash & Equivalents was $7.1 million for Q1 2026 at Champions Oncology, down from $8.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $10.8 million in Q4 2022 to a low of $2.6 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $6.3 million across 5 years, with a median of $5.5 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 50.05% in 2024, then surged 273.76% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $10.8 million in 2022, then tumbled by 49.08% to $5.5 million in 2023, then sank by 50.05% to $2.8 million in 2024, then jumped by 209.22% to $8.5 million in 2025, then slipped by 16.63% to $7.1 million in 2026.
• The last three Cash & Equivalents figures came in at $7.1 million (Q1 2026), $8.5 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.